Reducing dose to the lungs through loosing target dose homogeneity requirement for radiotherapy of n

来源 :2016年北京市肿瘤放疗年会 | 被引量 : 0次 | 上传用户:yty3224
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Purpose: It is important to minimize lung dose during intensity-modulated radiation therapy (IMRT) of non-small cell lung cancer (NSCLC).In this study, IMRT plans with inhomogeneous dose distributions are created in order to reduce the dose to lungs, especially the low dose region.And further reduce the incidence of radiation pneumonia of IMRT and increase the expected tumor control probability for NSCLC patients.Materials and Methods: Ten NSCLC patients with lung tumor on the right side treated at our institution between July 2014 and October 2015 were selected.The total dose for planning target volume (PTV) was 60 Gy (2Gy/fraction).For each patient, two IMRT plans with six beams were created in Pinnacle treatment planning system.The dose homogeneity of target was controlled by constraints on the maximum and uniform doses of target volume.One IMRT plan (IMRThome) was made with homogeneous target dose (the resulting target dose was within 95%-107% of the prescribed dose), while another IMRT plan (IMRTinho) was made with inhomogeneous target dose (the resulting target dose was more than 95% of the prescribed dose).During plan optimization, the dose of cord and heart in two types of IMRT plans were kept nearly the same.The doses of lungs, PTV and organs at risk (OARs) between two types of IMRT plans were compared and analyzed quantitatively.Results: For all patients, the lung dose was decreased in the IMRT plans with inhomogeneous target dose.On average, V20 of lungs decreased from 27.9±3.8% (IMRThomo) to 23.7±2.7% (IMRTinho) (p < 0.001), and the mean lungdose decreased from 15.7±2.1% (IMRThomo) to 14.1±1.8% (IMRTinho) (p < 0.001).V5 of lungs decreased from 57.1±8.3% (IMRThomo) to 51.6±7.4% (IMRTinho).V10 of lungs decreased from 42.6±7.1% (IMRThomo) to 37.4±6.4% (IMRTinho), and V30 of lungs decreased from 19.6±2.4% (IMRTinho) to 17.5±2.0% (IMRTinho).The dose to normal tissue was also reduced.There were no significant differences between the two IMRT plans on V25, V30, V40, V50 and mean dose for heart.The maximum doses of cords in two type IMRT plans were nearly the same.Conclusions: IMRT plans with homogeneous target dose could result in high dose to lung, and consequently increase the incidence of radiation pneumonia.IMRT plans with inhomogeneous target dose could protect lungs better and may be considered as a choice for treating NSCLC.
其他文献
目的:大分割放射治疗可以激活机体抗肿瘤免疫应答引起远位效应,本研究观察大分割放射治疗对患者免疫功能的影响,为后续的大分割放射治疗联合免疫治疗提供参考.材料与方法:(1)纳入标准:KPS≥70,年龄≥18岁;采用大分割治疗;(2)排除标准:处方剂量超过关键组织(脊髓、心脏等)耐受剂量;首次采样前21天内接受过化疗、靶向治疗或免疫治疗.2016年6-21至10-19符合入组条件17例患者,应用IGRT
The renal cell carcinoma (RCC) is one of the most common types of kidney neoplasia in Western countries;it is relatively resistant to conventional chemotherapy and radiotherapy.Metabolic disorders hav
全脑全脊髓放射治疗在临床上广泛应用于已发生或易于发生中枢神经系统(CNS)播散的颅内肿瘤,如髓母细胞瘤,松果体母细胞瘤,生殖细胞瘤等.因全脑全脊髓放疗照射范围广,治疗过程中会造成不同程度的血小板减少.轻者影响放放疗的顺利进行,进而影响治疗效果;重者则有可能导致自发性颅内出血危及患者生命.医院于2008年7月-2012年6月在给患者进行全脑全脊髓放疗的同时,给予重组人白细胞介素-11(rhIL-11
目的:探讨血管网织细胞瘤术后复发行放射治疗的可行性方法.方法:1例血管网织细胞瘤术后复发患者行适形调强放疗DT=54Gy/30f/6W,1.8Gy/f.结果:过程顺利,治疗结束后定期复查,肿瘤逐渐缩小.结论:放射治疗可作为血管网织细胞瘤术后复发的挽救性治疗.
Objective To guide a better clinical selection of radiation technology in the treatment of Graves ophthalmopathy by comparing the dose distribution and parameters of 3D-CRT technology, IMRT technology
目的:探讨一氧化氮对X线辐射诱导的不同p53基因状态的人肺癌细胞死亡和染色体畸变的双向性影响.方法:p53缺如的人肺癌H1299细胞通过稳定转染wtp53和mp53基因,得到本实验使用的野生型或突变型p53细胞.X线照射前,细胞作用于不同浓度的硝酸异山梨酯(ISDN,一种一氧化氮供体)和/或羧基-2-苯-4,4,5,5-四甲基咪唑-1-氧-3-氧化物(c-PTIO,一种一氧化氮清除剂).细胞敏感性
临床前研究表明大分割放疗可激活免疫应答,但在临床上鲜有探讨.本研究欲探索大分割放疗对恶性肿瘤患者细胞免疫功能的影响,分析其是否可激活患者免疫状态及激活的时间窗问题.
A 40-year-old Chinese female patient with radiation-induced brain necrosis after radiosurgery was treated with bevacizumab at a single dose of 200 mg (3.27 mg/kg) for 6 times, with an interval of 12-1
研究胸腺增生组织、胸腺瘤和胸腺癌中c-KIT蛋白产物的表达情况,探讨其在鉴别胸腺肿瘤良恶性中的价值及其与胸腺肿瘤的WHO病理分型、Masaoka分期、和预后的关系.
Objective This retrospective study investigated the efficacy and safety of bevacizumab treatment for refractory brain edema.Methods Bevacizumab was used for the treatment of 59 cases of brain metastat